BOND-003 With Dr. Mark D. Tyson: Cretostimogene for BCG-Unresponsive Bladder Cancer

4 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Mark D. Tyson, MD, of Mayo Clinic, discusses the data from cohort P of the BOND-003 trial, exploring the potential of cretostimogene grenadenorepvec in treating papillary-only BCG-unresponsive, non-muscle-invasive bladder cancer. He explains the trial’s focus on providing the urologic oncology community with data for informed treatment decisions, the unique mechanism of action exploiting RB pathway deficiencies, and the broader implications for bladder cancer care. Dr. Tyson also sheds light on FDA guidance that spurred innovation in this field and the critical importance of trials aimed at preserving bladder function in high-risk patients.
Category
Urology
Be the first to comment

Up Next